<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631654</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00080414</org_study_id>
    <nct_id>NCT03631654</nct_id>
  </id_info>
  <brief_title>Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes</brief_title>
  <official_title>Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ivabradine, a selective inhibitor of the If current in the sinoatrial node, provides heart
      rate reduction and leads to a reduction in heart failure hospitalizations. For this reason,
      the American College of Cardiology (ACC) and the American Heart Association (AHA) guidelines
      provide a class IIa recommendation for ivabradine in stable heart failure patients with LVEF
      35% and New York Heart Association (NYHA) class II-III symptoms who are on a beta blocker at
      maximum tolerated dose with a resting heart rate of 70 beats per minute or greater. While
      ivabradine leads to improvement in outcomes in stable NYHA class II-III chronic heart failure
      patients, its role in class IV, stage D heart failure, and cardiogenic shock is less clear.

      Ivabradine's effect on acute cardiogenic shock has been evaluated by two recent studies. In
      the MODIFY trial, a randomized control study evaluating ivabradine in patients with
      multiorgan dysfunction, the addition of ivabradine did not result in significant heart rate
      reductions or other positive clinical outcomes. However, a small prospective trial
      demonstrated a significant decrease in heart rate and NT-proBNP with the addition of
      ivabradine in patients with acute cardiogenic shock on dobutamine. While few data investigate
      ivabradine's role in acute cardiogenic shock, it has yet to be studied in heart failure
      patients on long-term inotropic therapy. Inotropes such as dobutamine and milrinone result in
      tachycardia and may lead to ventricular arrhythmias. Moreover, patients on chronic inotropes
      are typically off beta blockers and have few pharmacological options available to help reduce
      heart rates. Ivabradine may have a role in decreasing heart rate and improving outcomes in
      patients on chronic inotropes.

      Given the benefits of ivabradine in stable chronic heart failure patients, we plan to perform
      a study investigating the role of ivabradine in NYHA Stage D patients on home inotropes.

      Our primary objective is to analyze changes in two cardiac biomarkers, NT-proBNP and
      high-sensitivity troponin. Our secondary outcomes include changes in noninvasive
      echocardiographic hemodynamics, changes in arrhythmia burden, and heart failure symptom
      modification based on 6-minute walk test results.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac biomarkers</measure>
    <time_frame>One month</time_frame>
    <description>NT-pro BNP and high sensitivity troponin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Echocardiogram</measure>
    <time_frame>2 weeks, and one month</time_frame>
    <description>ejection fraction (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test</measure>
    <time_frame>2 weeks, and one month</time_frame>
    <description>Distance walked (meters) in 6 minutes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Heart Failure NYHA Class IV</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Ivabradine administration--tablets given 5 mg twice daily for 2 weeks, then 7.5 mg twice daily</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NYHA Stage D heart failure on 2 weeks of consecutive IV dobutamine or milrinone

          -  Followed at UMMC outpatient heart failure clinic or admitted to advanced heart failure
             inpatient service and planning to follow up at UMMC outpatient heart failure clinic

        Exclusion Criteria:

          -  Patients who are already on ivabradine

          -  Patients who are not willing to follow-up with UMMC outpatient heart failure team
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, College Park</investigator_affiliation>
    <investigator_full_name>Steve Gottlieb</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

